Last reviewed · How we verify
Metformin, VI-0521, Sitagliptan, Probenecid
At a glance
| Generic name | Metformin, VI-0521, Sitagliptan, Probenecid |
|---|---|
| Also known as | VI-0521, Sitagliptan, Metformin, Probenecid |
| Sponsor | VIVUS LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin, VI-0521, Sitagliptan, Probenecid CI brief — competitive landscape report
- Metformin, VI-0521, Sitagliptan, Probenecid updates RSS · CI watch RSS
- VIVUS LLC portfolio CI